The ascendancy of Viagra and its impact on the medicinal landscape presents a intricate question for investors. While the first sales figures were astounding, the intellectual property has ended, leading to a wave of off-brand alternatives that are reducing revenue. Furthermore, the sector is facing issues related to aging trends and evolving he… Read More